BioXcel Therapeutics Inc at Bank of America Global Healthcare Conference Transcript
Welcome to Day 1 of the Bank of America Healthcare Conference. I'm Greg Harrison, one of the biotech analysts here. And today, we have we have Vimal Mehta, the CEO; Rob Risinger, Chief Medical Officer; and Matt Wiley, Chief Commercial Officer of BioXcel. Thanks, guys, for joining us. Vimal, would you like to start off with any opening remarks, and then we'll jump into Q&A?
Thanks, Greg. Thank you, everyone, for joining us this morning. It's an extremely exciting time for BioXcel Therapeutics. We had our earnings call yesterday, so we laid it out why 2023 is extremely exciting. But I will highlight a couple of things. One, that our IGALMI launch, which is our commercial product for treatment of acute agitation resulting from schizophrenia bipolar 1 and 2 in adults, is progressing very well. And Matt is going to provide you more color around it. In addition to that, that opportunity allows us to capture 16
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |